Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tizanidine hydrochloride sustained-release preparation, preparation process and uses thereof

A technology for tizanidine hydrochloride and sustained-release preparations, applied in the field of tizanidine hydrochloride sustained-release tablets, can solve the problems of high blood drug concentration and obvious side effects, and achieve low blood drug concentration, small side effects, and bioavailability high effect

Active Publication Date: 2018-12-11
SICHUAN CREDIT PHARMA
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this sustained-release tablet still has the problems of high blood concentration and obvious side effects, and the sustained-release time is only 12 hours.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tizanidine hydrochloride sustained-release preparation, preparation process and uses thereof
  • Tizanidine hydrochloride sustained-release preparation, preparation process and uses thereof
  • Tizanidine hydrochloride sustained-release preparation, preparation process and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Tizanidine Hydrochloride

[0029] Grind and mix tizanidine hydrochloride, HPMC K100M, microcrystalline cellulose and pregelatinized starch, add PVP K30 solution prepared with 90% ethanol to make soft material, granulate, dry, granulate, add hard Magnesium fatty acid and micropowder silica gel are mixed evenly, and pressed into tablets to obtain the product.

Embodiment 2

[0031]

[0032]

[0033] The preparation method is the same as in Example 1.

Embodiment 3

[0035] Tizanidine Hydrochloride

[0036] The preparation method is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
viscosityaaaaaaaaaa
viscosityaaaaaaaaaa
viscosityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a tizanidine hydrochloride sustained-release preparation and a preparation method thereof, wherein the tizanidine hydrochloride sustained-release preparation contains tizanidine hydrochloride, a sustained-release skeleton material, a filler, a binder and a glidant according to a certain ratio. According to the present invention, the tizanidine hydrochloride sustained-release preparation can maintain the sustained release effect for 24 h, can avoid the excessive fluctuation of blood drug concentration and improve medication safety, effectiveness and compliance after taking, and further can reduce side effects; and the preparation process is simple, and the controllability of the process is strong.

Description

technical field [0001] The invention relates to a tizanidine hydrochloride sustained-release preparation and its preparation process and application, in particular to a tizanidine hydrochloride sustained-release tablet. Background technique [0002] TiazanidineHydrochloride is a central skeletal muscle relaxant with an imidazoline structure, the chemical name is 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2, 1,3-benzothiadiazol-4-amine, its molecular structure is as follows: [0003] [0004] It is currently the only new type of central skeletal muscle relaxant and central α2 adrenoceptor agonist with gastrointestinal protective effects on the market. It was first developed by Novartis in Switzerland and first released in Denmark in 1988. It was launched in Switzerland and Switzerland, and subsequently obtained sales licenses in more than 20 countries including Europe, the United States, and Japan. It is clinically used for the treatment of increased skeletal muscle tensio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K47/38A61K31/433A61P21/02A61P29/00
CPCA61K9/0002A61K9/2054A61K31/433
Inventor 赵领魏郁梦皮超梁婧陶建林
Owner SICHUAN CREDIT PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com